Theriva Biologics (TOVX)
XASE:TOVX
Top Page
Theriva Biologics
(NYSE MKT:TOVX)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.21
▲(3.00% Upside)
Action:ReiteratedDate:03/24/26
The score is primarily held down by weak financial performance (no revenue, sustained losses, and continued cash burn with erosion of equity), implying ongoing reliance on financing. Technicals are mixed-to-neutral with only modest near-term improvement versus a weaker long-term trend. Corporate events are a partial offset due to constructive Phase 3 regulatory alignment for VCN-01, but funding/governance uncertainty remains, and valuation has limited support given negative earnings and no dividend.
Positive Factors
Regulatory alignment for VCN-01 Phase 3
Regulatory concurrence from the FDA on a pivotal Phase 3 design (endpoints, repeat dosing, adaptive interim analyses) materially reduces development execution risk. This durable endorsement increases the probability a single global protocol can support approval, strengthens partnering leverage, and helps justify resource allocation and manufacturing scale-up over the next 2–6 months.
Negative Factors
Persistent negative cash generation
Consistent negative operating cash flow (worsening from roughly -$12.9M in 2021 to about -$16.7M in 2025) and persistently negative free cash flow create an ongoing need for external financing. This structural cash burn constrains execution flexibility, makes timelines dependent on capital raises or partnerships, and raises dilution risk until a partnering or funding event materializes.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory alignment for VCN-01 Phase 3
Regulatory concurrence from the FDA on a pivotal Phase 3 design (endpoints, repeat dosing, adaptive interim analyses) materially reduces development execution risk. This durable endorsement increases the probability a single global protocol can support approval, strengthens partnering leverage, and helps justify resource allocation and manufacturing scale-up over the next 2–6 months.
Read all positive factors
Theriva Biologics (TOVX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.28M
Dividend YieldN/A
Average Volume (3M)8.88M
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue GrowthN/A
EPS Growth83.25%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.85
Shares Outstanding45,892,670
10 Day Avg. Volume25,882,304
30 Day Avg. Volume8,875,558
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-0.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit118.79
Enterprise Value/Ebitda0.22
Forecast
1Y Price Target
$2.11Price Target Upside955.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.2
Revenue Forecast (FY)$29.37M
Theriva Biologics Business Overview & Revenue Model
Company Description
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiot...
How the Company Makes Money
Theriva Biologics is a clinical-stage company and does not have a stable, recurring product-revenue base typical of commercial-stage pharmaceutical firms; as a result, its operating model is primarily funded through external capital and, when avai...
Theriva Biologics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -108.00K | 0.00 | 0.00 | 0.00 | -87.00K |
| EBITDA | -14.91M | -19.29M | -21.96M | -19.20M | -14.19M |
| Net Income | -25.25M | -25.65M | -18.35M | -19.68M | -14.27M |
Balance Sheet | |||||
| Total Assets | 38.24M | 35.35M | 55.22M | 71.86M | 70.36M |
| Cash, Cash Equivalents and Short-Term Investments | 13.06M | 11.61M | 23.18M | 41.79M | 67.33M |
| Total Debt | 2.63M | 1.56M | 2.15M | 1.68M | 1.53M |
| Total Liabilities | 22.86M | 16.29M | 15.52M | 17.30M | 4.96M |
| Stockholders Equity | 15.38M | 19.07M | 39.70M | 54.56M | 65.41M |
Cash Flow | |||||
| Free Cash Flow | -16.70M | -16.94M | -19.20M | -19.20M | -12.90M |
| Operating Cash Flow | -16.67M | -16.94M | -19.00M | -19.08M | -12.89M |
| Investing Cash Flow | -35.00K | -1.00K | -202.00K | -4.40M | -14.00K |
| Financing Cash Flow | 18.19M | 5.50M | 625.00K | -1.93M | 74.00M |
Theriva Biologics Technical Analysis
Positive
0.20
Price Trends
0.19
Positive
0.21
Positive
0.32
Negative
Market Momentum
<0.01
Negative
67.38
Neutral
41.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TOVX, the sentiment is Positive. The current price of 0.2 is above the 20-day moving average (MA) of 0.19, above the 50-day MA of 0.19, and below the 200-day MA of 0.32, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 67.38 is Neutral, neither overbought nor oversold. The STOCH value of 41.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TOVX.
Theriva Biologics Risk Analysis
Theriva Biologics disclosed 60 risk factors in its most recent earnings report. Theriva Biologics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Theriva Biologics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $9.28M | -0.10 | -209.36% | ― | ― | 83.25% | |
46 Neutral | $1.51M | -0.02 | -197.11% | ― | ― | 99.87% | |
45 Neutral | $3.59M | -1.19 | -157.24% | ― | ― | 25.19% | |
44 Neutral | $2.77M | -1.00 | -46.34% | ― | ― | 70.71% |
* Healthcare Sector Average
TOVX
Theriva Biologics
0.20
-0.90
-81.64%
GLMD
Galmed Pharmaceuticals
0.50
-0.94
-65.00%
MTNB
Matinas BioPharma
0.56
0.04
7.69%
CNSP
CNS Pharmaceuticals
2.44
-13.88
-85.05%
Theriva Biologics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Theriva Biologics Advances VCN-01 Into Pivotal Phase 3
Positive
Mar 23, 2026
On March 23, 2026, Theriva Biologics reported that a recent Type B End-of-Phase 2 meeting with the U.S. Food and Drug Administration yielded broad agreement on the design of a pivotal Phase 3 trial of VCN-01 plus gemcitabine/nab-paclitaxel for fir...
Business Operations and StrategyProduct-Related Announcements
Theriva Licenses SYN-020, Refocuses on Cancer Pipeline
Positive
Feb 18, 2026
On February 18, 2026, Theriva Biologics entered into a license agreement granting Rasayana Therapeutics an exclusive worldwide right to develop and commercialize SYN-020, an oral recombinant intestinal alkaline phosphatase designed to address meta...
Private Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
Theriva Biologics Faces Delay in Warrant Approval Meeting
Negative
Feb 12, 2026
On February 11, 2026, Theriva Biologics, Inc. attempted to hold a Special Meeting of Stockholders but was unable to convene it because there were not enough shares present or represented by proxy to constitute a quorum. The company will now call a...
Business Operations and StrategyProduct-Related Announcements
Theriva Biologics advances VCN-01 toward Phase 3 trial
Positive
Jan 12, 2026
Theriva Biologics has updated investors on progress preparing a Phase 3 clinical trial for its lead oncolytic virus VCN-01 in first-line metastatic pancreatic cancer, supported by encouraging Phase 2b VIRAGE data showing improved overall and progr...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Theriva Biologics Gains EMA Backing for VCN-01 Phase 3
Positive
Dec 29, 2025
On December 29, 2025, Theriva Biologics reported that it received positive Scientific Advice from the European Medicines Agency’s Committee for Medicinal Products for Human Use on the design of a pivotal Phase 3 trial of its lead oncolytic a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.